A phase 1b dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of alintegimod (ALIN) + ipilimumab (Ipi) followed by nivolumab (Nivo) in advanced solid tumor patients (SITC 2026) - Oct 2, 2026 - Abstract #549; Pres time: Nov 6, 2026; 10:00 AM - 07:00 PM; Location: PCC - Lower Level - North Exhibition Halls 4-5-6; No abstract available
Clinical • Metastases • P1 data • PK/PD data • Oncology • Solid Tumor
|
|
Matthew Hadfield; Alexander Philipovskiy; Konstantin Dragnev; Sapna Patel; William Schary; Nicole Gallegos; Siddhartha De; Shankar Sengottuvelan; Jeffery Actor; Darren Woodside; Yared Hailemichael; Willem Overwijk; Nada Elsayed; Upendra Marathi; Lionel Lewis; Apostolia Tsimberidou
|